These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29379162)

  • 1. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
    Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 3. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.
    Rodgers LH; Ó hAinmhire E; Young AN; Burdette JE
    Oncotarget; 2016 May; 7(22):32785-95. PubMed ID: 27129161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.
    de Cristofaro T; Di Palma T; Soriano AA; Monticelli A; Affinito O; Cocozza S; Zannini M
    Oncotarget; 2016 Jul; 7(27):41929-41947. PubMed ID: 27259239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
    Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
    J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
    Hua G; Lv X; He C; Remmenga SW; Rodabough KJ; Dong J; Yang L; Lele SM; Yang P; Zhou J; Karst A; Drapkin RI; Davis JS; Wang C
    Oncogene; 2016 Apr; 35(17):2247-65. PubMed ID: 26364602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
    Hardy LR; Pergande MR; Esparza K; Heath KN; Önyüksel H; Cologna SM; Burdette JE
    Oncogene; 2019 Aug; 38(32):6003-6016. PubMed ID: 31296958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
    Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
    Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.
    Hatano Y; Fukuda S; Makino H; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2018 Apr; 13(1):24. PubMed ID: 29703236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 expression in fallopian tube epithelium drives cell migration.
    Quartuccio SM; Karthikeyan S; Eddie SL; Lantvit DD; Ó hAinmhire E; Modi DA; Wei JJ; Burdette JE
    Int J Cancer; 2015 Oct; 137(7):1528-38. PubMed ID: 25810107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
    Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.